Challenges And Solutions Around Diversity And Inclusion In Clinical Trials During A Pandemic
Source: Life Science Leader
Rob Wright, chief editor of Life Science Leader, conducted a virtual roundtable with four CEOs of publicly traded biopharmas (view full video here). In this component, Rachel King, CEO of GlycoMimetics, (NASDAQ: GLYC), Jeremy Levin, D.Phil., MB BChir, CEO, Ovid Therapeutics (NASDAQ: OVID), Gil Van Bokkelen, Ph.D., chairman and CEO of Athersys (NASDAQ: ATHX), and Ted Love, M.D., CEO of Global Blood Therapeutics (NASDAQ: GBT), discuss some of the challenges and solutions for making clinical trials diverse and inclusive during the pandemic.
This website uses cookies to ensure you get the best experience on our website. Learn more